Dendreon
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dendreon sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Dendreon: 18 sponsored US clinical trials, 1 recruiting.
Dendreon sponsors 18 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 13 completed. 4 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 2 trials.
Top-decile sponsor footprint
Dendreon ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (76.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT06134232
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
NCT03686683
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
NCT01981122
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
NCT01727154
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
NCT01981109
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
NCT01487863
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
NCT01338012
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
NCT01431391
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
NCT01353222
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
NCT01306890
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
NCT00901342
Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
NCT00839631
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
NCT00715078
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
NCT00715104
Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)
NCT00849290
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
NCT00065442
PROvenge Treatment and Early Cancer Treatment
NCT00779402
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005947
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 10 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the Dendreon pipeline
1 recruiting of 18 indexed (6% open); 13 completed (72%).
Phase mix: 4 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (2 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dendreon: open-pipeline peers nationwide
Peers matched on 18 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Dendreon sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Boston College · 6% recruiting · 18 trials
- CytoDyn · 6% recruiting · 18 trials
- Intercept Pharmaceuticals · 6% recruiting · 18 trials
- NGM Biopharmaceuticals · 6% recruiting · 18 trials
Related
What to do with this Dendreon page
18 registered trials is a research-attention snapshot, not an endorsement of Dendreon or any single study.
- 1 of Dendreon's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Dendreon studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Dendreon pipeline card: 18 registered trials from official public datasets.Report a data error.